Britta Hardy

1.1k total citations
58 papers, 919 citations indexed

About

Britta Hardy is a scholar working on Molecular Biology, Immunology and Cell Biology. According to data from OpenAlex, Britta Hardy has authored 58 papers receiving a total of 919 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 23 papers in Immunology and 15 papers in Cell Biology. Recurrent topics in Britta Hardy's work include Immunotherapy and Immune Responses (14 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Endoplasmic Reticulum Stress and Disease (9 papers). Britta Hardy is often cited by papers focused on Immunotherapy and Immune Responses (14 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Endoplasmic Reticulum Stress and Disease (9 papers). Britta Hardy collaborates with scholars based in Israel, United States and New Zealand. Britta Hardy's co-authors include Annat Raiter, Barbara F. Heslop, Alexander Battler, Ehud Skutelsky, Chana Weiss, Rinat Yerushalmi, Yaron Niv, Abraham Novogrodsky, D. Danon and Riva Kovjazin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Cell Biology and The Journal of Immunology.

In The Last Decade

Britta Hardy

58 papers receiving 846 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Britta Hardy Israel 21 357 323 218 156 139 58 919
Takaichi Shimozato Japan 17 439 1.2× 520 1.6× 196 0.9× 160 1.0× 69 0.5× 30 1.2k
Thorsten Sadowski Germany 17 399 1.1× 166 0.5× 121 0.6× 341 2.2× 113 0.8× 33 1.2k
A. Matter Switzerland 15 596 1.7× 261 0.8× 90 0.4× 207 1.3× 79 0.6× 42 1.2k
Panagiotis Karagiannis United Kingdom 19 486 1.4× 558 1.7× 152 0.7× 420 2.7× 133 1.0× 42 1.5k
Esther P.M. Tjin Netherlands 19 497 1.4× 461 1.4× 260 1.2× 284 1.8× 69 0.5× 33 1.2k
Jack Longley United States 16 235 0.7× 474 1.5× 141 0.6× 113 0.7× 55 0.4× 32 935
L Marshall-Carlson United States 9 705 2.0× 321 1.0× 149 0.7× 82 0.5× 86 0.6× 9 1.4k
N. Kraft Australia 19 341 1.0× 355 1.1× 75 0.3× 105 0.7× 99 0.7× 48 1.0k
Stefan Gustafson Sweden 16 377 1.1× 111 0.3× 366 1.7× 56 0.4× 120 0.9× 37 904
K Konrad Austria 18 201 0.6× 175 0.5× 257 1.2× 145 0.9× 41 0.3× 64 1.1k

Countries citing papers authored by Britta Hardy

Since Specialization
Citations

This map shows the geographic impact of Britta Hardy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Britta Hardy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Britta Hardy more than expected).

Fields of papers citing papers by Britta Hardy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Britta Hardy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Britta Hardy. The network helps show where Britta Hardy may publish in the future.

Co-authorship network of co-authors of Britta Hardy

This figure shows the co-authorship network connecting the top 25 collaborators of Britta Hardy. A scholar is included among the top collaborators of Britta Hardy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Britta Hardy. Britta Hardy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hardy, Britta & Annat Raiter. (2013). New era in cancer immunotherapy: Twenty years to the discovery of monoclonal antibodies harnessing the immune system to eradicate tumors. Advances in Bioscience and Biotechnology. 4(4). 34–37. 1 indexed citations
2.
Hardy, Britta, et al.. (2012). Colon cancer cells expressing cell surface GRP78 as a marker for reduced tumorigenicity. Cellular Oncology. 35(5). 345–354. 26 indexed citations
3.
Goldenberg‐Cohen, Nitza, et al.. (2011). Peptide-binding GRP78 protects neurons from hypoxia-induced apoptosis. APOPTOSIS. 17(3). 278–288. 33 indexed citations
4.
Raiter, Annat, et al.. (2010). Angiogenic Peptides Improve Blood Flow and Promote Capillary Growth in a Diabetic and Ischaemic Mouse Model. European Journal of Vascular and Endovascular Surgery. 40(3). 381–388. 11 indexed citations
5.
Hardy, Britta & Annat Raiter. (2010). Peptide-binding heat shock protein GRP78 protects cardiomyocytes from hypoxia-induced apoptosis. Journal of Molecular Medicine. 88(11). 1157–1167. 31 indexed citations
6.
Raiter, Annat, et al.. (2010). Activation of GRP78 on Endothelial Cell Membranes by an ADAM15-Derived Peptide Induces Angiogenesis. Journal of Vascular Research. 47(5). 399–411. 33 indexed citations
7.
Damianovich, Maya, Miri Blank, Annat Raiter, Britta Hardy, & Yehuda Shoenfeld. (2009). Anti-vascular endothelial growth factor (VEGF) specific activity of intravenous immunoglobulin (IVIg). International Immunology. 21(9). 1057–1063. 7 indexed citations
8.
Shohat, M., et al.. (2009). A new method for isolation of human antisperm antibodies. Andrologia. 28(5). 275–279. 1 indexed citations
9.
Ben‐Dor, Itsik, Britta Hardy, Shmuel Fuchs, et al.. (2007). Repeated Low-dose of Erythropoietin is Associated with Improved Left Ventricular Function in Rat Acute Myocardial Infarction Model. Cardiovascular Drugs and Therapy. 21(5). 339–346. 14 indexed citations
10.
Nudelman, I, Sara Morgenstern, Alex Geller, et al.. (2007). Gallbladder Inflammation is Associated with Increase in Mucin Expression and Pigmented Stone Formation. Digestive Diseases and Sciences. 52(7). 1613–1620. 37 indexed citations
11.
Hardy, Britta, et al.. (2007). Therapeutic angiogenesis of mouse hind limb ischemia by novel peptide activating GRP78 receptor on endothelial cells. Biochemical Pharmacology. 75(4). 891–899. 40 indexed citations
12.
Hardy, Britta, Annat Raiter, Chana Weiss, et al.. (2006). Angiogenesis induced by novel peptides selected from a phage display library by screening human vascular endothelial cells under different physiological conditions. Peptides. 28(3). 691–701. 23 indexed citations
13.
Hardy, Britta & Annat Raiter. (2005). A mimotope peptide-based anti-cancer vaccine selected by BAT monoclonal antibody. Vaccine. 23(34). 4283–4291. 34 indexed citations
14.
Quaglino, Elena, Cristina Mastini, Manuela Iezzi, et al.. (2005). The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice. Vaccine. 23(25). 3280–3287. 17 indexed citations
15.
Feinmesser, Raphael, et al.. (2003). Report of a Clinical Trial in 12 Patients With Head and Neck Cancer Treated Intratumorally and Peritumorally With Multikine. Archives of Otolaryngology - Head and Neck Surgery. 129(8). 874–874. 7 indexed citations
16.
Hardy, Britta, et al.. (2001). Treatment with BAT monoclonal antibody decreases tumor burden in a murine model of leukemia/lymphoma. International Journal of Oncology. 19(5). 897–902. 9 indexed citations
17.
Raiter, Annat, et al.. (2001). Effect of exogenous thyroid‐stimulating hormone on thyroid papillary carcinoma cells in tissue culture. Head & Neck. 23(6). 479–483. 3 indexed citations
18.
Raiter, Annat, et al.. (2000). CD4+ T lymphocytes as a primary cellular target for BAT mAb stimulation. International Immunology. 12(11). 1623–1628. 8 indexed citations
19.
Wasserman, Lina, et al.. (1995). Monoclonal antibodies against native ovarian tumor cells: specificity and characterization of the antigen. A preliminary report. Journal of Cancer Research and Clinical Oncology. 121(7). 387–392. 2 indexed citations
20.
Hardy, Britta, et al.. (1989). A monoclonal antibody to human B lymphoblastoid cells activates human and murine T lymphocytes. Cellular Immunology. 118(1). 22–29. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takaichi Shimozato Breakdown of academic impact, for papers by Thorsten Sadowski Breakdown of academic impact, for papers by A. Matter Breakdown of academic impact, for papers by Panagiotis Karagiannis Breakdown of academic impact, for papers by Esther P.M. Tjin Breakdown of academic impact, for papers by Jack Longley Breakdown of academic impact, for papers by L Marshall-Carlson Breakdown of academic impact, for papers by N. Kraft Breakdown of academic impact, for papers by Stefan Gustafson Breakdown of academic impact, for papers by K Konrad
Rankless by CCL
2026